SSRI/SNRI + Esketamine for depressive disorder, treatment-resistant

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 2 Apr 2021: Trial registered, NCT04829318
  2. 26 Apr 2021: Trial started, NCT04829318

The trials

NCT04829318: A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment

State
Completed
Phase
Phase 4
People
183 taking part
Started
26 Apr 2021
Primary completion
22 Jul 2024
Arms
Esketamine
Results
Posted on the registry
  1. 2 Apr 2021: Trial registered
  2. 26 Apr 2021: Trial started
  3. 22 Jul 2024: Trial completed
  4. 18 Sep 2025: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.